Sign in

ZBH on NYSE

Zimmer Biomet Holdings

Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons5

American medical device company

Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.3 Its shares trade on NYSE under the symbol ZBH.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1927Founded1

Compare with Intuitive Surgical, Edwards Lifesciences or Steris, or pick any stock.

  • TickerZBH on NYSE1
  • Industrybiomedical engineering1
  • HeadquartersWarsaw1
  • Founded inWarsaw1
  • Websitewww.zimmer.com
  • Legal formDelaware corporation1
  • Listed onNew York Stock Exchange (ZBH), Swiss Stock Exchange (ZBH)1
  • Incorporated inDE6
  • Business address345 East Main Street, Warsaw, In 465806
  • Filer categoryLarge accelerated filer6
  • LEI2P2YLDVPES3BXQ1FRB914
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 33437994

See how the biggest companies compare on our leaderboards

Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

13.3%Operating margin9
8.6%Net margin9
7.2%Revenue growth, 20259
5.6%Return on equity9
0.55×Debt to equity9
$1.5BFree cash flow9

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Knees brought in 40% of the revenue Zimmer Biomet Holdings broke down this way in fiscal 2025.

  1. Knees$3.3B940%up 5% from 2024
  2. SET$2.2B926%up 15% from 2024
  3. Hips$2.1B925%up 5% from 2024
  4. Technology And Data, Bone Cement and Surgical$665.6M98%up 4% from 2024
Products and services by year
Products and services202320242025
Knees$3.0B$3.2B$3.3B
SET$1.8B$1.9B$2.2B
Hips$2.0B$2.0B$2.1B
Technology And Data, Bone Cement and Surgical$636.0M$640.3M$665.6M

Regions

Americas brought in 31% of the revenue Zimmer Biomet Holdings broke down this way in fiscal 2025.

  1. Americas$5.1B931%up 7% from 2024
  2. United States$4.8B929%up 7% from 2024
  3. Rest of the world$3.5B921%up 7% from 2024
  4. EMEA$1.8B911%up 8% from 2024
  5. Asia Pacific$1.3B98%up 5% from 2024
Regions by year
Regions202320242025
Americas$4.6B$4.8B$5.1B
United States$4.3B$4.4B$4.8B
Rest of the world$3.1B$3.2B$3.5B
EMEA$1.6B$1.7B$1.8B
Asia Pacific$1.2B$1.2B$1.3B

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue30¢$2.5B
  • Selling, general and admin40¢$3.3B
  • Other costs20¢$1.6B
  • Income tax2¢$125.7M
  • Profit9¢$705.1M

Out of $8.2B in revenue.9

Where each dollar of operating cash went, fiscal 2025

  • Capital spending13¢$224.5M
  • Dividends paid11¢$190.3M
  • Share buybacks29¢$487.0M
  • Kept or used elsewhere47¢$795.3M

Out of $1.7B of cash from operations.9

Financial statements

Revenue101112139$8.2B in 2025+3% since 2019
0$2.5B$5.0B$7.5B$10.0B2019: $8.0B$8.0B20192020: $6.1B$6.1B2020−23%2021: $6.8B$6.8B2021+11%2022: $6.9B$6.9B2022+2%2023: $7.4B$7.4B2023+7%2024: $7.7B$7.7B2024+4%2025: $8.2B$8.2B2025+7%
Operating income101112139$1.1B in 2025−3% since 2019
0$500.0M$1.0B$1.5B2019: $1.1B$1.1B20192020: $83.1M$83.1M2020−93%2021: $860.3M$860.3M2021+935%2022: $696.3M$696.3M2022−19%2023: $1.3B$1.3B2023+83%2024: $1.3B$1.3B2024+1%2025: $1.1B$1.1B2025−15%
Net income101112139$705.1M in 2025−38% since 2019
-$500.0M0$500.0M$1.0B$1.5B2019: $1.1B$1.1B20192020: -$138.9M-$138.9M20202021: $401.6M$401.6M20212022: $231.4M$231.4M2022−42%2023: $1.0B$1.0B2023+343%2024: $903.8M$903.8M2024−12%2025: $705.1M$705.1M2025−22%

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
Net Sales$8.2B$7.7B$7.4B
Cost of products sold, excluding intangible asset amortization$2.5B$2.2B$2.1B
Intangible asset amortization$665.9M$591.9M$561.5M
Research and development$458.5M$437.4M$458.7M
Selling, general and administrative$3.3B$2.9B$2.8B
Restructuring and other cost reduction initiatives$181.2M$219.0M$151.9M
Acquisition, integration, divestiture and related$76.9M$23.6M$21.7M
Operating expenses$7.1B$6.4B$6.1B
Operating Profit$1.1B$1.3B$1.3B
Other income (expense), net$25.5M-$31.1M-$9.3M
Interest expense, net-$292.8M-$218.0M-$201.2M
Earnings before income taxes$830.8M$1.0B$1.1B
Provision for income taxes$125.7M$131.4M$42.2M
Net Earnings$705.1M$905.2M$1.0B
Less: Net (loss) earnings attributable to noncontrolling interest-$100.0K$1.5M$1.1M
Net Earnings of Zimmer Biomet Holdings, Inc.$705.1M$903.8M$1.0B
Basic$3.56$4.45$4.91
Diluted$3.55$4.43$4.88
Basic198.0M shares203.1M shares208.7M shares
Diluted198.7M shares203.9M shares209.7M shares

Compare Zimmer Biomet Holdings with another company

Corporate structure

Zimmer Biomet Holdings sits at the top of its group. 155 entities, 49 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Zimmer Biomet Holdings

  • &. Cox Dodge Filed SCHEDULE 13G/A on Zimmer Biomet Holdings, latest Aug 13, 2026 (6 filings since Feb 13, 2024)
  • Capital International Investors Filed SCHEDULE 13G on Zimmer Biomet Holdings, latest Aug 12, 2026
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SCHEDULE 13G/A on Zimmer Biomet Holdings, latest May 15, 2026 (4 filings since Feb 14, 2023)
  • VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Zimmer Biomet Holdings, latest Apr 30, 2026
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Zimmer Biomet Holdings, latest Mar 27, 2026 (5 filings since Feb 10, 2022)
  • HARRIS ASSOCIATES L P Filed SCHEDULE 13G on Zimmer Biomet Holdings, latest Feb 17, 2026
  • BlackRock Filed SCHEDULE 13G/A on Zimmer Biomet Holdings, latest Apr 17, 2025 (5 filings since Jan 28, 2022)
  • JPMorgan Chase Filed SC 13G/A on Zimmer Biomet Holdings, latest Nov 7, 2022 (2 filings since Jan 28, 2022)
  • Zimmer Biomet Holdings Warsaw, Indiana, United States
    • Zimmer Wilmington, Delaware, United States
    • Zimmer Biomet (Germany) Subsidiary · Berlin, Germany
    • Zimmer Biomet (Switzerland) Subsidiary · Winterthur, Switzerland
    • Zimmer Biomet (United Kingdom) Subsidiary · Bridgend, United Kingdom
    • Monogram Technologies Inc. Stake · Austin, Texas
    • ZimVie Inc. Stake · Westminster, Colorado, United States
    • zimmer biomet Subsidiary · 100% · Warsaw, United States
    • 3-102-910623 Sociedad de Responsabilidad Limitada Subsidiary · Costa Rica
    • A&E Medical Corp. Subsidiary · New Jersey, United States
    • Alto Development Corp. Subsidiary · New Jersey, United States
    • Avitus Orthopaedics, Inc. Subsidiary · Delaware, United States
    • Beijing Montagne Medical Device Co., Ltd. Subsidiary · China
    • Biomet Argentina SA Subsidiary · Argentina
    • Biomet Biologics, LLC Subsidiary · Indiana, United States
    • Biomet C.V. Subsidiary · Netherlands
    • Biomet Chile SA Subsidiary · Chile
    • Biomet China Co., Ltd. Subsidiary · China
    • Biomet CV Holdings, LLC Subsidiary · Delaware, United States
    • Biomet Deutschland GmbH Subsidiary · Germany
    • Biomet Fair Lawn LLC Subsidiary · Indiana, United States
    • Biomet France Sarl Subsidiary · France
    • BIOMET GLOBAL SUPPLY CHAIN CENTER BV Subsidiary · Warsaw, Indiana, United States
    • Biomet Hong Kong Holding Ltd. Subsidiary · Hong Kong
    • Biomet International, Inc. Subsidiary · Delaware, United States
    • Biomet Manufacturing, LLC Subsidiary · Indiana, United States
    • and 129 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.

What it owns

What Zimmer Biomet Holdings reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$7.3B9 Dec 31, 2025$6.7B9 Dec 31, 2024+8.5%
Accumulated depreciation$5.1B9 Dec 31, 2025$4.6B9 Dec 31, 2024+8.8%
Property and equipment, net$2.2B9 Dec 31, 2025$2.0B9 Dec 31, 2024+7.7%
Operating-lease assets (leased space)$204.2M9 Dec 31, 2025$213.5M9 Dec 31, 2024−4.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$591.9M9 Dec 31, 2025$525.5M9 Dec 31, 2024+12.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$9.9B9 Dec 31, 2025$9.0B9 Dec 31, 2024+11.1%
Intangible assets, net (excluding goodwill)$4.7B9 Dec 31, 2025$4.6B9 Dec 31, 2024+2.6%
Indefinite-lived intangibles (excluding goodwill)$675.4M9 Dec 31, 2025$450.0M9 Dec 31, 2024+50.1%
Finite-lived intangibles, gross$10.4B9 Dec 31, 2025$9.7B9 Dec 31, 2024+6.5%
Accumulated amortization$6.3B9 Dec 31, 2025$5.6B9 Dec 31, 2024+13.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$2.3B9 Dec 31, 2025$2.2B9 Dec 31, 2024+2.3%
Raw materials$273.2M9 Dec 31, 2025$288.5M9 Dec 31, 2024−5.3%
Work in process$181.0M9 Dec 31, 2025$175.1M9 Dec 31, 2024+3.4%
Finished goods$1.8B9 Dec 31, 2025$1.8B9 Dec 31, 2024+3.4%

Properties, in its own words

We own or lease approximately 300 different facilities around the world, of which approximately half are in the U.S. Our corporate headquarters is in Warsaw, Indiana. Warsaw, Indiana is also home to our most significant manufacturing, research and development (“R&D”) and other business activities for our Knees, Hips and S.E.T.

product divisions. Internationally, our EMEA regional headquarters is in Switzerland and our Asia Pacific regional headquarters is in Singapore.

The rest of Item 2

We have approximately 25 manufacturing locations in the U.S. and internationally. Our most significant locations outside of the U.S. are in Switzerland, Ireland and China. We primarily own our manufacturing facilities in the U.S.; internationally, we occupy both owned and leased manufacturing facilities.

We maintain sales and administrative offices and warehouse and distribution facilities in more than 45 countries around the world. These local market facilities are primarily leased due to common businesses practices and to allow us to be more adaptable to changing needs in the market.

We distribute our products both through large, centralized warehouses and through smaller, market specific facilities, depending on the needs of the market. We maintain large, centralized warehouses in the U.S. and the Netherlands to be able to efficiently distribute our products to customers in the U.S. and EMEA.

We believe that all of the facilities and equipment are in good condition, well maintained and able to operate at present levels. We believe the current facilities, including manufacturing, warehousing, R&D and office space, provide sufficient capacity to meet ongoing demands.

Item 2 of the 10-K filed Feb 20, 2026.17

The story

Zimmer Biomet was established in 1927 by Justin O. Zimmer (1884–1951) in Warsaw, Indiana.

On April 24, 2014, it was announced that Zimmer had agreed to purchase Biomet Inc. for $13.4 billion. In October 2014, however, it was announced that the EU's antitrust regulators had opened an extensive investigation into Zimmer's bid for Biomet due to concern that it would substantially lessen competition in certain markets. In March 2016, European Commission (“EC”) conditionally cleared Zimmer's proposed acquisition of Biomet, Inc. and on June 24, 2015, Zimmer completed its acquisition of Biomet forming Zimmer Biomet Holdings.

In October 2014, the company announced it would acquire ETEX Holdings, Inc.

In March 2016, Zimmer Biomet announced it would acquire Ortho Transmission, LLC. The company also announced it would acquire sports medicine company, Cayenne Medical, Inc. Later in the same year the company acquired medical device manufacturer, LDR Holding Corporation for $37 per share ($1 billion in total), merging it into their Spine division. In July, the company acquired French surgical robotics company Medtech. In August, the company announced it was acquiring Delaware-based CD Diagnostics, a diagnostics company developing immunoassays and biomarker testing. In September, Zimmer announced the acquisition of Clinical Graphics, B.V.

The Justin Zimmer House in Warsaw is listed on the National Register of Historic Places.

In January 2023, the company announced its intention to acquire Embody, Inc. for $155 million (plus a potential $120 million in milestones).

In August 2024, Zimmer Biomet announced plans to acquire OrthoGrid Systems, an AI surgical guidance company, in order to expand its market share in hip replacement procedures.

On October 7, 2025, Zimmer Biomet completed its acquisition of Monogram Technologies Inc. (formerly NASDAQ:MGRM), an orthopedic robotics company.

Read the full text

In 2026, Zimmer Biomet acquired the iovera pain therapy business from Pacira BioSciences Inc. for $140 million.

From Wikipedia’s article on Zimmer Biomet, shared under CC BY-SA 4.0.7

Leadership

Who has led Zimmer Biomet Holdings, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John Raymond Elliott2006–2007
  2. David C. Dvorak2007–2017
  3. Daniel P. Florin2017
  4. Bryan C. Hanson2017–2023
  5. Ivan Tornos2023–now

Chair

  1. Bruno A. Melzi2006–2013
  2. John Raymond Elliott2006–2007
  3. Ivan Tornos2026–now

President

  1. Jon E. Kramer2006–2008
  2. Stephen Hong Liang Ooi2006–2015
  3. David C. Dvorak2007–2017
  4. Joseph A. Cucolo2012–2014
  5. Adam Rudolph Johnson2015–2017
  6. Daniel E. Williamson2015–2018
  7. David A. Nolan Jr.2015–2018
  8. Sang Yi2015–2017
  9. Stuart G. Kleopfer2015–2016
  10. Robert D. Delp2017–2018
  11. Bryan C. Hanson2017–2023
  12. Aure Bruneau2018–2019
  13. Didier Deltort2018–2021
  14. Ivan Tornos2018–2023
  15. Mark Bezjak2023–2025
  16. Chintan Desai2026–now

Chief financial officer

  1. Sam R. Leno2006–2007
  2. James T. Crines2007–2015
  3. Daniel P. Florin2015–2019
  4. Suketu Upadhyay2019–now

Chief operating officer

  1. Ivan Tornos2021–2023
197019801990200020102020
Board members and other officers (44)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerWilfred F. van Zuilen named Feb 15, 202384

Products and brands

Zimmer designs, develops, manufactures and markets orthopedics products, including knee, hip, shoulder, elbow, foot and ankle artificial joints and dental prostheses. In 2024, Zimmer introduced the ROSA Shoulder, said to be the world's first robotic surgery system for shoulder replacement, and the fourth application for the company's ROSA Robotics portfolio, which includes the ROSA Knee System for total knee arthroplasty and ROSA Hip System for total hip replacement. Zimmer has operations in more than 40 countries around the world (US, Australia, Austria, Belgium, Canada, China, Czech Republic, Finland, France, Germany, India, Ireland, Israel, Italy, Japan, Latin America, Netherlands, Brasil, Poland, Portugal, Russia, South Africa, Spain etc.) and sells products in more than 100 countries.

From Wikipedia’s article on Zimmer Biomet, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • 3-102-910623 Sociedad de Responsabilidad Limitada Costa Rica8
  • A&E Medical Corp. New Jersey8
  • Alto Development Corp. New Jersey8
  • Avitus Orthopaedics, Inc. Delaware8
  • Beijing Montagne Medical Device Co., Ltd. China8
  • Biomet Argentina SA Argentina8
  • Biomet Biologics, LLC Indiana8
  • Biomet C.V. Netherlands8
  • Biomet CV Holdings, LLC Delaware8
  • Biomet Chile SA Chile8
  • Biomet China Co., Ltd. China8
  • Biomet Deutschland GmbH Germany8
  • Biomet Fair Lawn LLC Indiana8
  • Biomet France Sarl France8
  • Biomet Global Supply Chain Center B.V. Netherlands8
  • Biomet Holdings B.V. Netherlands8
  • Biomet Hong Kong Holding Ltd. Hong Kong8
  • Biomet International, Inc. Delaware8
  • Biomet Manufacturing, LLC Indiana8
  • Biomet Mexico S.A. de C.V. Mexico8
  • Biomet Microfixation, LLC Florida8
  • Biomet Orthopedics, LLC Indiana8
  • Biomet Spain Orthopaedics S.L.U. Spain8
  • Biomet Sports Medicine, LLC Indiana8
All 155 listed subsidiaries
  • Biomet Trauma, LLC Indiana8
  • Biomet U.S. Reconstruction, LLC Indiana8
  • Biomet UK Healthcare Limited United Kingdom8
  • Biomet UK Ltd. United Kingdom8
  • Biomet, Inc. Indiana8
  • CD Diagnostics, Inc. Delaware8
  • CD Laboratories, Inc. Maryland8
  • Cayenne Medical, Inc. Delaware8
  • Changzhou Biomet Medical Devices Co., Ltd. China8
  • Citra Labs, LLC Indiana8
  • Disior Oy Finland8
  • Dornoch Medical Systems, Inc. Illinois8
  • ETEX Corporation Massachusetts8
  • ETEX Holdings, Inc. Delaware8
  • Embody, Inc. Virginia8
  • Interpore Cross International, LLC California8
  • LVB Acquisition, Inc. Delaware8
  • Medtech SAS France8
  • Medtech Surgical, Inc. Delaware8
  • Monogram Technologies Inc. Delaware8
  • Neosteo SAS France8
  • ORTHOsoft ULC Canada8
  • OSSIS Corporation New Zealand8
  • OrthoGrid Systems SAS France8
  • OrthoGrid Systems, Inc. Delaware8
  • Paragon 28 Australia PTY LTD Australia8
  • Paragon 28 DE GmbH Germany8
  • Paragon 28 Italia SRL Italy8
  • Paragon 28 Japan K.K. Japan8
  • Paragon 28 Medical Devices Trading Limited Ireland8
  • Paragon 28 Medical Devices Trading Limited, Cape Town Branch (branch) South Africa8
  • Paragon 28 UK, LTD United Kingdom8
  • Paragon 28, Inc. Delaware8
  • ReLign Corporation Delaware8
  • Representaciones Zimmer Inc., S. de R.L. de C.V. Mexico8
  • Shanghai Biomet Business Consulting Co., Ltd. China8
  • V.I.M.S. VIDEO INTERVENTIONNELLE MEDICALE SCIENTIFIQUE SA France8
  • WM World Medical Importacao e Exportacao Ltda. Brazil8
  • ZB COOP C.V. Netherlands8
  • ZB Cayman (Asia) Holding Ltd. Cayman Islands8
  • ZB EMEA Finance UK 1 Ltd. United Kingdom8
  • ZB Hong Kong Holding Ltd. Hong Kong8
  • ZB Hong Kong Ltd. Hong Kong8
  • ZB Manufacturing, LLC Delaware8
  • ZB UK Group Holdings Limited United Kingdom8
  • ZB UK Plant Holdings Limited United Kingdom8
  • Zhejiang Biomet Medical Products Co., Ltd. China8
  • Zimmer (Shanghai) Medical International Trading Co., Ltd. China8
  • Zimmer (Shanghai) Medical International Trading Co., Ltd. - Beijing Branch (branch) China8
  • Zimmer Asia (HK) Ltd. Hong Kong8
  • Zimmer Australia Holding Pty. Ltd. Australia8
  • Zimmer Biomet (Thailand) Co., Ltd. Thailand8
  • Zimmer Biomet Asel Alarabiya Limited Company Saudi Arabia8
  • Zimmer Biomet Asia Holding B.V. Netherlands8
  • Zimmer Biomet Asia Holdings Pte. Ltd. Singapore8
  • Zimmer Biomet Austria GmbH Austria8
  • Zimmer Biomet BV Belgium8
  • Zimmer Biomet Brasil Ltda. Brazil8
  • Zimmer Biomet CBT China8
  • Zimmer Biomet CMFT Holdings, LLC Delaware8
  • Zimmer Biomet Canada, Inc. Canada8
  • Zimmer Biomet Centroamerica SA Costa Rica8
  • Zimmer Biomet Colombia SAS Colombia8
  • Zimmer Biomet Contract Solutions, LLC Delaware8
  • Zimmer Biomet Denmark ApS Denmark8
  • Zimmer Biomet Deutschland GmbH Germany8
  • Zimmer Biomet Finance Srl Barbados8
  • Zimmer Biomet Finland Oy Finland8
  • Zimmer Biomet France Holdings SAS France8
  • Zimmer Biomet France SAS France8
  • Zimmer Biomet G.K. Japan8
  • Zimmer Biomet Global Holdings Switzerland GmbH Switzerland8
  • Zimmer Biomet Healthcare Management GmbH Germany8
  • Zimmer Biomet Hellas SA Greece8
  • Zimmer Biomet Integrations LLC Delaware8
  • Zimmer Biomet Ireland Holdings Limited Ireland8
  • Zimmer Biomet Ireland Limited Ireland8
  • Zimmer Biomet Italia Srl Italy8
  • Zimmer Biomet Leasing LLC Delaware8
  • Zimmer Biomet Medical Israel Ltd. Israel8
  • Zimmer Biomet NZ Holdings Corporation New Zealand8
  • Zimmer Biomet Nederland B.V. Netherlands8
  • Zimmer Biomet New Zealand Company New Zealand8
  • Zimmer Biomet Norway AS Norway8
  • Zimmer Biomet OUS Holdings 1 GmbH Switzerland8
  • Zimmer Biomet OUS Holdings GmbH Liechtenstein8
  • Zimmer Biomet Polska Sp. z.o.o Poland8
  • Zimmer Biomet Portugal, Unipessoal Lda Portugal8
  • Zimmer Biomet Pty. Ltd. Australia8
  • Zimmer Biomet Romania S.R.L. Romania8
  • Zimmer Biomet South Africa (Pty) Ltd. South Africa8
  • Zimmer Biomet Spain S.L.U. Spain8
  • Zimmer Biomet Sweden AB Sweden8
  • Zimmer Biomet Taiwan Co., Ltd. Taiwan8
  • Zimmer Biomet Tibbi Cihazlar Sanayi ve Ticaret Anonim Sirketi Turkey8
  • Zimmer Biomet UK Limited United Kingdom8
  • Zimmer CIS Ltd. Russia8
  • Zimmer CV, Inc. Delaware8
  • Zimmer Caribe, LLC Delaware8
  • Zimmer Co-op Holdings, LLC Delaware8
  • Zimmer Czech sro Czech Republic8
  • Zimmer Germany Holdings GmbH Germany8
  • Zimmer GmbH Switzerland8
  • Zimmer GmbH Representative Office Lebanon (branch) Lebanon8
  • Zimmer GmbH, Distribution (branch) Switzerland8
  • Zimmer GmbH, Euro IP Branch (branch) Switzerland8
  • Zimmer GmbH, Zimmer Biomet Regional Headquarters (branch) Saudi Arabia8
  • Zimmer GmbH, Zug Branch (branch) Switzerland8
  • Zimmer Gulf FZ LLC United Arab Emirates8
  • Zimmer India Private Ltd. India8
  • Zimmer International Logistics GmbH Germany8
  • Zimmer Knee Creations, Inc. Delaware8
  • Zimmer Luxembourg II Sarl Luxembourg8
  • Zimmer Luxembourg Sarl Luxembourg8
  • Zimmer Manufacturing B.V. Netherlands8
  • Zimmer Manufacturing B.V. (Puerto Rico Branch) Puerto Rico8
  • Zimmer Medical Malaysia SDN BHD Malaysia8
  • Zimmer Orthobiologics, Inc. New Jersey8
  • Zimmer Orthopedics Manufacturing Limited Ireland8
  • Zimmer Production, Inc. Delaware8
  • Zimmer Pte. Ltd. Singapore8
  • Zimmer Pte. Ltd., The Representative Office of Zimmer Pte. Ltd. in Hanoi City (branch) Vietnam8
  • Zimmer Slovakia sro Slovakia8
  • Zimmer Surgical SA Switzerland8
  • Zimmer Surgical, Inc. Delaware8
  • Zimmer Switzerland Holdings LLC Switzerland8
  • Zimmer Switzerland Manufacturing GmbH Switzerland8
  • Zimmer Trabecular Metal Technology, Inc. New Jersey8
  • Zimmer Trustee Limited United Kingdom8
  • Zimmer US, Inc. Delaware8
  • Zimmer, Inc. Delaware8

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

  1. 2015Biomet became a subsidiary1

The following is an illustration of the company's major mergers, acquisitions and historical predecessors:

From Wikipedia’s article on Zimmer Biomet, shared under CC BY-SA 4.0.7

Former names

  • ZIMMER HOLDINGS INCMar 26, 2001 to Jun 8, 20156

Timeline

  1. Sep 8, 20268-K Executive or director change; Regulation FD disclosure85
  2. Aug 5, 20268-K Results of operations86
  3. Aug 5, 20268-K Other events87
  4. Jun 29, 20268-K Entered a material agreement; Ended a material agreement; New debt or obligation88
  5. May 27, 20268-K Shareholder vote89
  6. May 12, 20268-K Regulation FD disclosure90
  7. Apr 28, 20268-K Results of operations91
  8. Apr 28, 20268-K Executive or director change; Regulation FD disclosure92
  9. Feb 10, 20268-K Results of operations93
  10. Jan 12, 20268-K Executive or director change94
  11. Nov 5, 20258-K Results of operations95
  12. Oct 7, 20258-K Other events96
  13. Sep 6, 2023New chief executive Ivan Tornos becomes CEO18
  14. Dec 21, 2017New chief executive Bryan C. Hanson becomes CEO20
  15. Aug 3, 2017New chief executive Daniel P. Florin becomes CEO19
  16. May 2, 2007New chief executive David C. Dvorak becomes CEO21
  17. Jan 20, 2006New chief executive John Raymond Elliott becomes CEO22
  18. 1927Founded Founded in Warsaw1

Calendar

Coming up

  1. Nov 4, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $1.90 a share, on Nov 5, 2025.97

When it reported results

  1. Aug 5, 2026Reported quarterly or annual results86
  2. Apr 28, 2026Reported quarterly or annual results91
  3. Feb 10, 2026Reported quarterly or annual results93
  4. Nov 5, 2025Reported quarterly or annual results95
  5. Aug 7, 2025Reported quarterly or annual results98
  6. May 5, 2025Reported quarterly or annual results99
  7. Feb 6, 2025Reported quarterly or annual results100
  8. Oct 30, 2024Reported quarterly or annual results101

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

604 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 68 major events, 418 insider forms, 25 large holders, 1 private raises, 72 other. The latest 20:

  1. Oct 5, 20264 EDGAR
  2. Oct 5, 20263 EDGAR
  3. Oct 5, 20263 EDGAR
  4. Oct 2, 20264 EDGAR
  5. Oct 2, 20264 EDGAR
  6. Oct 2, 20264 EDGAR
  7. Oct 2, 20264 EDGAR
  8. Oct 2, 20264 EDGAR
  9. Oct 2, 20264 EDGAR
  10. Oct 2, 20264 EDGAR
  11. Sep 15, 20264 EDGAR
  12. Sep 11, 2026144 EDGAR
  13. Sep 9, 20264 EDGAR
  14. Sep 8, 20268-K EDGAR
  15. Sep 4, 2026144 EDGAR
  16. Aug 13, 2026SCHEDULE 13G/A EDGAR
  17. Aug 12, 2026SCHEDULE 13G EDGAR
  18. Aug 5, 20264 EDGAR
  19. Aug 5, 20268-K EDGAR
  20. Aug 5, 202610-Q EDGAR

The 604 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 7 buys and 19 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 11, 2026Thornal Kevin RGrp Pres-Global BusinessSale5,691$92.95$529.0KForm 4
Sep 4, 2026Phipps Chad FSee remarks below.Sale3,000$98.35$295.1KForm 4
May 29, 2026Yi SangGroup President, Asia PacificSale5,000$82.64$413.2KForm 4
Mar 12, 2026Winkler LoriSVP and CHROSale2,650$94.66$250.8KForm 4
Feb 12, 2026Yi SangGroup President, Asia PacificSale1,000$96.49$96.5KForm 4
Sep 11, 2025Yi SangGroup President, Asia PacificSale1,200$103.59$124.3KForm 4
Sep 8, 2025Winkler LoriSVP and CHROSale1,500$104.15$156.2KForm 4
Aug 18, 2025Winkler LoriSVP and CHROSale1,500$102.49$153.7KForm 4
Jun 13, 2025Yi SangGroup President, Asia PacificSale800$92.51$74.0KForm 4
Jun 11, 2025Yi SangGroup President, Asia PacificSale1,000$95.00$95.0KForm 4
Mar 5, 2025Winkler LoriSVP and CHROSale1,443$104.40$150.6KForm 4
May 31, 2024Yi SangGroup President, Asia PacificSale12,857$114.69$1.5MForm 4
Mar 7, 2024Yi SangGroup President, Asia PacificSale1,705$126.86$216.3KForm 4
Feb 22, 2024Phipps Chad FSee remarks below.Sale26,156$128.62$3.4MForm 4
Nov 9, 2023Jafry Syed A.DirectorBuy2,135$104.75$223.6KForm 4
Aug 30, 2023Kolli SreelakshmiDirectorBuy1,000$120.37$120.4KForm 4
Aug 28, 2023BEGLEY CHRISTOPHER BDirectorBuy1,000$117.11$117.1KForm 4
Aug 28, 2023HAGEMANN ROBERTDirectorBuy2,000$116.48$233.0KForm 4
Aug 25, 2023MICHELSON MICHAEL WDirectorBuy1,300$115.50$150.2KForm 4
Aug 25, 2023BERNARD BETSY JDirectorBuy871$114.84$100.0KForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Stakes it holds

Zimmer Biomet Holdings has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Ivan Tornos50$1.3M$16.1M112
2025Jehanzeb Noor$683.0K$7.9M112
2025Suketu Upadhyay$906.8K$6.2M112
2025Kevin Thornal$405.4K$6.2M112
2025Wilfred van Zuilen$743.1K$4.1M112
2024ChairmanPresident$1.2M$15.0M112
2024CFO and EVP - Finance,$876.2K$5.9M112
2024Group PresidentEMEA$666.3K$3.5M112
2023Operations and Supply Chain$801.8K$10.4M112
2023and CEO$968.7K$10.2M112
2023Group PresidentEMEA$629.3K$3.4M112

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 6, 2023Raised $216.1 million in a private offering of equity Form D: 157 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Dodge & Cox24,124,735$2.1B1.1%+582,035
BlackRock, Inc.15,614,847$1.3B0.0%+274,041
Harris Associates L P12,738,025$1.1B1.5%−221,914
Vanguard Capital Management LLC12,634,937$1.1B0.0%−158,475
Capital International Investors12,183,614$1.0B0.2%+3,064,392
State Street Corp8,877,171$766.3M0.0%+52,044
Vanguard Portfolio Management LLC8,441,747$726.7M0.0%−208,481
Geode Capital Management, LLC5,349,223$458.7M0.0%−30,302
Invesco Ltd.3,979,860$342.6M0.0%+374,435
Primecap Management Co/ca/3,816,680$328.6M0.2%−90,470
Van Eck Associates Corp3,501,654$301.5M0.2%−262,266
Citadel Advisors LLC3,477,472$299.4M0.2%+2,098,807
Hotchkis & Wiley Capital Management LLC2,761,429$237.7M0.7%−30,960
UBS Group AG2,758,615$237.5M0.0%+1,385,250
American Century Companies Inc2,744,463$236.3M0.1%−1,218,743
Morgan Stanley2,591,503$223.1M0.0%+561,688
Bank Of America Corp /de/2,177,724$187.5M0.0%+627,934
Northern Trust Corp1,965,052$169.2M0.0%−58,015
Dimensional Fund Advisors LP1,958,313$168.7M0.0%−265,850
Equity Investment Corp1,681,360$144.7M2.8%−62,944
Norges Bank1,587,431$136.7M0.0%New
Arrowstreet Capital, Limited Partnership1,562,139$134.5M0.1%+457,921
Legal & General Group Plc1,465,529$126.2M0.0%−71,412
Manufacturers Life Insurance Company, The1,458,259$125.5M0.1%−47,501
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1,457,553$125.5M0.0%−12,667

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

14 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 27, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000−15.2%Report
May 15, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$1,001 - $15,000+33.1%Report
Apr 8, 2025Robert P. Bresnahan, Jr.Republican, HouseBuy$1,001 - $15,000−63.6%Report
Feb 11, 2025Julie JohnsonDemocratic, HouseSale$1,001 - $15,000+32.2%Report
Nov 28, 2022Nicholas V. Taylor, HouseSale$100,001 - $250,000+114.7%Report
Jul 28, 2022Lois FrankelDemocratic, HouseSale$1,001 - $15,000+104.9%Report
Jun 13, 2022Lois FrankelDemocratic, HousePartial sale$1,001 - $15,000+120.1%Report
Sep 30, 2021Susie LeeDemocratic, HouseSale$15,001 - $50,000+113.4%Report
Jun 28, 2021Susie LeeDemocratic, HouseBuy$1,001 - $15,000−121.2%Report
Dec 16, 2020Susie LeeDemocratic, HouseBuy$1,001 - $15,000−143.2%Report
Dec 8, 2020Susie LeeDemocratic, HouseBuy$1,001 - $15,000−142.2%Report
Dec 3, 2020Susie LeeDemocratic, HouseBuy$1,001 - $15,000−144.0%Report
Apr 27, 2020Lois FrankelDemocratic, HousePartial sale$1,001 - $15,000+186.1%Report
Apr 3, 2020Susie LeeDemocratic, HousePartial sale$1,001 - $15,000+205.3%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Zimmer Biomet Holdings is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARZIMMER BIOMET HOLDINGS, INC.2
  • CIK0001136869
  • Employer ID (EIN)13-415177717
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
  • Incorporated inDelaware17
  • Fiscal year endsDecember 312
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address345 East Main Street, Warsaw, IN 465802
  • Phone57426761312
  • Shares outstanding190,737,689 as of Jul 30, 202615
  • Public float$18.0B as of Jun 30, 202517
  • AuditorPricewaterhouseCoopers LLP, Chicago, Illinois PCAOB ID 238; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceMar 26, 20012
  • Filings2,644 in all: 4 (1,608), 8-K (322), 425 (101), 10-Q (76), 3 (66), SC 13G/A (50), SC 13G (28), 424B5 (26)2
    All 57 form types

    DEF 14A (25), 10-K (24), DEFA14A (23), SC TO-T/A (23), 144 (22), UPLOAD (21), S-8 (20), ARS (18), 11-K (17), FWP (16), S-8 POS (16), CORRESP (13), SD (13), SC 13D/A (12), 4/A (11), S-3ASR (7), S-4/A (7), SCHEDULE 13G/A (7), 424B7 (6), 424B3 (5), 8-K/A (5), SC 13D (5), SC TO-C (5), 10-12B/A (4), 3/A (4), PRE 14A (4), S-4 (4), 8-A12B (3), SCHEDULE 13G (3), CERT (2), DFAN14A (2), PRER14A (2), SC TO-T (2), 10-12B (1), 10-K405 (1), 10-Q/A (1), 25-NSE (1), 5 (1), 5/A (1), CERTNYS (1), D (1), DEFM14A (1), DEFR14A (1), EFFECT (1), IRANNOTICE (1), NO ACT (1), PREM14A (1), RW (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Feb 20, 2026
    Quarterly report (10-Q) Aug 5, 2026
    Proxy statement (DEF 14A) Apr 1, 2026
    Latest 8-K (8-K) Sep 8, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par valueZBHNew York Stock Exchange
2.425% Notes due 2026ZBH 26New York Stock Exchange
1.164% Notes due 2027ZBH 27New York Stock Exchange
3.518% Notes due 2032ZBH 32New York Stock Exchange

From the cover page of the 10-K filed Feb 20, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks Zimmer Biomet Holdings names in Item 1A of its 10-K filed Feb 20, 2026: 32 risks under these headings, as written.17

  • Risks Related to our Business, Operations and Strategy
  • Our success depends on our ability to effectively develop and market our products against those of our competitors.
  • Our products may become obsolete, customers may not buy our products, and our revenue and profitability may decline without the timely introduction of new products and enhancements, due to changes in markets, changes in our strategy, or due to changes in applicable standards of care.
  • Our success largely depends on our ability to attract, retain, develop and motivate our human capital, including our senior management, key employees and key third parties, and on our ability to have meaningful succession plans in place to prepare for foreseen and unforeseen changes.
  • We are transforming aspects of our sales and distribution network and go-to-market model in the U.S. and certain other markets, and these efforts may not be successful and they involve risks and challenges that may adversely impact our business, results of operations and financial condition.
  • Our restructuring programs may not be successful or we may not fully realize the expected cost savings and/or operating efficiencies from our restructuring initiatives.
  • Our product portfolio rationalization activities may not be successful or we may not fully realize the expected cost savings and/or operating efficiencies from our portfolio rationalization initiatives.
  • We may not be able to effectively integrate acquired businesses into our operations or achieve expected cost savings or profitability from our acquisitions.
  • Interruption of manufacturing or distribution operations could adversely affect our business, financial condition and results of operations.
  • Challenges integrating, transitioning and implementing a new enterprise resource planning ("ERP") system have adversely affected our business and operations, and may in the future have further adverse effects.
  • Disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products by us or third-party suppliers could adversely affect our business, financial condition and results of operations.
  • We and our business partners are dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems and data, including from cybersecurity events, our business could be adversely affected.
The other 21 risks
  • Business interruptions and disruptions have adversely impacted, and may, either alone or in combination with other risks, in the future adversely impact, our business, results of operations and financial condition, the nature and extent of which impacts are uncertain and unpredictable.
  • If third-party payors decline to reimburse our customers for our products or reduce reimbursement levels, the demand for our products may decline and our ability to sell our products profitably may be harmed. In addition, we are subject to cost containment measures in the United States and other countries, resulting in pricing pressures, which could have a material adverse effect on our business, results of operations, and cash flows.
  • Natural disasters, or legal, regulatory or market measures to address natural disasters, could materially adversely affect our business and financial results.
  • Our commitments, goals and disclosures related to corporate responsibility matters, and the perception of our activities in these areas, may adversely impact us.
  • Financial, Credit and Liquidity Risks
  • We incurred substantial additional indebtedness in connection with previous mergers and acquisitions, may incur additional substantial indebtedness in connection with future mergers and acquisitions, and may not be able to meet all of our current and future debt obligations. In addition, interest rate risk could adversely affect our current and future indebtedness.
  • Changes in tax laws in countries in which we do business are expected to negatively impact our effective tax rate; further changes in tax laws may have a further negative impact.
  • We may have additional tax liabilities as a result of examinations and audits.
  • If our independent agents and distributors are characterized as employees, we would be subject to additional tax and other liabilities.
  • Future material impairments in the carrying value of our intangible assets, including goodwill, would negatively affect our operating results.
  • The spinoff of ZimVie Inc. and the divestiture of our retained interest in ZimVie Inc. could result in substantial tax liability.
  • Global Operational Risks
  • We conduct a significant amount of our sales and manufacturing activities outside of the U.S., which subjects us to additional business risks and may cause our profitability to decline due to increased costs.
  • Tariffs, trade restrictions and other trade measures have adversely affected, and could continue to adversely affect, our business and financial results.
  • We are subject to risks arising from currency exchange rate fluctuations, which can increase our costs, cause our profitability to decline and expose us to counterparty risks.
  • Legal, Regulatory and Compliance Risks
  • We are subject to complex and expensive laws and governmental regulations relating to the development, design, product standards, packaging, advertising, promotion, post-market surveillance, manufacturing, labeling and marketing of our products, non-compliance with which could adversely affect our business, financial condition and results of operations.
  • If we fail to comply with healthcare fraud and abuse laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
  • If we fail to comply with data privacy and security laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
  • Pending and future product liability claims and litigation could adversely impact our financial condition and results of operations and impair our reputation.
  • We are substantially dependent on patent and other proprietary rights, and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in the payment of significant monetary damages and/or royalty payments, negatively impact our ability to sell current or future products, or prohibit us from enforcing our patent and other proprietary rights against others.
  • We are involved in legal proceedings that may result in adverse outcomes.
  • Risks Related to Our Organizational Documents and Jurisdiction of Incorporation
  • Anti-takeover provisions in our organizational documents could delay or prevent a change of control.
  • Our Restated By-Laws designate certain Delaware courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.

Legal proceedings

Information pertaining to certain legal proceedings in which we are involved can be found in Note 20 to our consolidated financial statements included in Part II, Item 8 of this report and is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
    SEC EDGAROther events
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
    SEC EDGAROther events
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109
  110. 110
  111. 111
  112. 112